Consistent with these data, we observed inhibition of KIT mRNA expression and reduced viability in response to ATO (an FDA-approved drug with multiple effects, including GLI1/2 inhibition) in GIST cell lines with different KIT mutations, including GIST cells with KIT mutation that renders GIST resistant to TKI therapies. Here, GLI1 is linked to gastrointestinal stromal tumor.